Treatment of Cognitive Deficits in Schizophrenia With Atomoxetine: A Case Report

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Schizophrenia patients have deficits in attention, concentration, and information processing that result in significant functional impairment.¹ Atomoxetine, a novel cognitive enhancer that can reduce executive function deficits,² has been postulated to potentially treat these deficits in schizophrenia.³ We report a patient with schizophrenia whose cognitive functioning improved after adjunctive treatment with atomoxetine.’ ‹’ ‹